August 9, 2024 – Goldea Capital

The Keg Royalties Income Fund announces August 2024 cash distribution

Written by Customer Service on August 9, 2024. Posted in Dividend Reports And Estimates.

VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its August 2024 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at August 21, 2024. The August 2024 distribution will be paid on August 30, 2024. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. With approximately 10,000 employees, over 100 restaurants and annual system sales exceeding...

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

Written by Customer Service on August 9, 2024. Posted in Public Companies.

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request that Lykos Therapeutics complete a third confirmatory Phase 3 trial prior to allowing the approval of MDMA assisted therapy (MDMA-AT) for the treatment of Post Traumatic Stress Disorder. “PharmAla does not operate in the US except as a clinical trial supplier, and as such this decision will have a limited impact on our operations in the near-term. USFDA has an important responsibility to get things right, and we believe that they are acting in good faith, however...

Premier Diversified Holdings Inc. Announces Shares for Debt Transaction

Written by Customer Service on August 9, 2024. Posted in Public Companies.

Not for dissemination in the United States of America VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) — Premier Diversified Holdings Inc. (“PDH” or the “Company”) (TSXV:PDH) is pleased to announce that it has entered into a debt settlement agreement to settle outstanding debt in the aggregate amount of CAD$5,927,164 (the “Debt“) owing to a creditor of the Company (the “Creditor“), by issuing 29,635,820 common shares (the “Conversion Shares“) of the issuer resulting from the previously announced reverse takeover of the Company by AJA Health and Wellness Inc., Assured Diagnosis Inc., and AJA Therapeutics Inc. (the “RTO Transaction“) at a deemed price of $0.20 per Conversion Share (the “Shares for Debt Transaction“). The Board of Directors...

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Written by Customer Service on August 9, 2024. Posted in Public Companies.

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. “Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions,” said Punit Dhillon, CEO of Skye. “In Q2, at our event, ‘Metabolic...

Diversified Royalty Corp. Announces Second Quarter 2024 Results and Strongest Adjusted Revenue¹ Quarter in its History

Written by Customer Service on August 9, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months ended June 30, 2024 (“Q2 2024”) and six months ended June 30, 2024. Highlights The weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 4.4% in Q2 2024 and 5.0% for the six months ended June 30, 2024 compared to 10.3% for the three months ended June 30, 2023 (“Q2 2023”) and 10.5% for the six months ended June 30, 2023. The weighted average organic royalty growth1 on a constant currency basis was 4.1% in Q2 2024 and 4.9% for the six months ended June 30, 2024. Revenue of $16.8 million in Q2 2024 and $31.9 million for the six months ended June 30, 2024, up 18.6% and 20.3%, respectively, compared...

Ascot Reports Second Quarter 2024 Results

Written by Customer Service on August 9, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce the Company’s unaudited financial results for the three and six months ended June 30, 2024 (“Q2 2024”), located on Nisga’a Nation Treaty Lands in the prolific Golden Triangle of northwestern British Columbia. For details of the unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three and six months ended June 30, 2024, please see the Company’s filings on SEDAR+ (www.sedarplus.ca). All amounts herein are reported in $000s of Canadian dollars (“C$”) unless otherwise specified. Q2 2024 AND RECENT HIGHLIGHTS On July 25, 2024, the Company closed the previously announced bought deal financing, including the full...

Nasdaq Announces End of Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 31, 2024

Written by Customer Service on August 9, 2024. Posted in Public Companies.

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) — At the end of the settlement date of July 31, 2024, short interest in 3,043 Nasdaq Global MarketSM securities totaled 11,985,723,964 shares compared with 12,309,469,231 shares in 3,044 Global Market issues reported for the prior settlement date of July 15, 2024. The end of July short interest represent 2.90 days average daily Nasdaq Global Market share volume for the reporting period, compared with 2.95 days for the prior reporting period. Short interest in 1,692 securities on The Nasdaq Capital MarketSM totaled 2,082,532,251 shares at the end of the settlement date of July 31, 2024 compared with 2,046,452,681 shares in 1,687 securities for the previous reporting period. This represents a 1.29 day average daily volume; the previous reporting period’s figure was 1.43. In summary, short...

Constellation Software Inc. Announces Results for the Second Quarter Ended June 30, 2024 and Declares Quarterly Dividend

Written by Customer Service on August 9, 2024. Posted in Dividend Reports And Estimates.

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30, 2024 and declared a $1.00 per share dividend payable on October 10, 2024 to all common shareholders of record at close of business on September 20, 2024. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2024 and the accompanying notes, our Management Discussion and Analysis for the three and...

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Written by Customer Service on August 9, 2024. Posted in Earnings Releases And Operating Results.

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase 1b & 2/3 (“DRAGON II”) trial of Tinlarebant in adolescent STGD1 patients has been initiated and have completed enrollment for Phase 1b with six subjects in Japan Tinlarebant granted Orphan Drug and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1 Pivotal global Phase 3 trial of Tinlarebant in GA subjects (“PHOENIX”) is ongoing and approximately 200 subjects have been enrolled Data from a 24-month Phase 2 trial in adolescents with STGD1 showed a sustained, lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics...

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

Written by Customer Service on August 9, 2024. Posted in Earnings Releases And Operating Results.

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclerosis, a common obesity-related metabolic complication, is expected to be available H2-2024. IC 100 Investigational New Drug (IND) submission planned for Q4-2024, to be followed by initiation of a Phase 1 clinical trial in obesity with metabolic complications expected to begin Q1-2025. Raised approximately $0.8 million from exercise of investor warrants. WESTON, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing...

Day: August 9, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice